← back to search

Begonya Comin-Anduix

University of Colorado Denver · US
🔎 Find collaborators in Oncology · Immunology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, CAR-T cell therapy research, Melanoma and MAPK Pathways, and Cancer Immunotherapy and Biomarkers.
h-index
30
citations
6,437
works
122
NIH funding
primary concept
Medicine
email

Recent publications

IL-13Rα2/TGF-<b>β</b> bispecific CAR-T cells counter TGF-<b>β</b>-mediated immune suppression and potentiate anti-tumor responses in glioblastoma
Neuro-Oncology 2024cited by 52position: middledoi
Pigs as Clinically Relevant Models for Synergizing Interventional Oncology and Immunotherapy
Journal of Vascular and Interventional Radiology 2024cited by 8position: middledoi
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Cell 2020cited by 527position: middledoi
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
The Journal of Steroid Biochemistry and Molecular Biology 2019cited by 66position: middledoi
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Cell Reports 2017cited by 1,886position: middledoi
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance
Proceedings of the National Academy of Sciences 2017cited by 246position: middledoi
Tremelimumab: research and clinical development
OncoTargets and Therapy 2016cited by 80position: middledoi
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
OncoImmunology 2015cited by 100position: middledoi
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Molecular Cancer 2015cited by 64position: middledoi
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Clinical Cancer Research 2014cited by 329position: middledoi
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Molecular Cancer 2014cited by 123position: middledoi
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
OncoImmunology 2014cited by 91position: middledoi
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Molecular Cancer 2014cited by 80position: middledoi
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
Cancer Discovery 2013cited by 147position: middledoi
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Cancer Research 2012cited by 233position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Antoni Ribas · UCLA Medical Center10 papers (2012–2017)Thomas G. Graeber · Nanosys (United States)6 papers (2012–2017)Lídia Robert · University of California, Los Angeles5 papers (2014–2017)Michael Cerniglia · University of Southern California4 papers (2014–2015)Amanda Lassen · Lillebaelt Hospital4 papers (2014–2015)Earl Avramis · Fate Therapeutics (United States)4 papers (2013–2015)Deborah J. Wong · University of California, Los Angeles4 papers (2014–2015)Richard C. Koya · Roswell Park Comprehensive Cancer Center4 papers (2012–2017)Mohammad Atefi · Namazi Hospital4 papers (2014–2015)Thinle Chodon · Illinois Arts Council Agency3 papers (2012–2014)David Foulad · Stanford University3 papers (2014–2015)Helena Escuin-Ordinas · Highlight Therapeutics (Spain)3 papers (2015–2017)Stephen Mok · The University of Texas MD Anderson Cancer Center3 papers (2012–2015)Blanca Homet Moreno · Merck & Co., Inc., Rahway, NJ, USA (United States)3 papers (2015–2017)Roger S. Lo · University of California, Los Angeles2 papers (2014–2017)James R. Heath · Sandia National Laboratories2 papers (2013–2017)Ángel García-Díaz · Instituto de Parasitología y Biomedicina "López - Neyra"2 papers (2017–2017)Bjoern Titz · Roche (Switzerland)2 papers (2014–2015)Siwen Hu‐Lieskovan · University of Utah Health Care2 papers (2015–2017)Paul C. Tumeh · University of California, Los Angeles2 papers (2012–2014)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Immunology →